Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer
Abstract Colorectal cancer is a malignant tumor of the colon or rectum, with approximately 150,000 new cases each year. Current treatment strategies, such as surgery, chemotherapy, radiotherapy, and immunotherapy, face challenges ranging from cancer recurrence, drug resistance to significant toxicit...
Saved in:
| Main Authors: | Ying Zhang, Jing Du, Xiaohong Cui, Yuhang Ling, Chengwu Tang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-07-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-025-02652-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01) -
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
by: Peter Jung, et al.
Published: (2024-12-01) -
Expression and clinical significance of GUCY2C in colorectal cancer: implications for targeted therapy
by: Liu Lu, et al.
Published: (2025-02-01) -
Potent ferroptosis agent RSL3 induces cleavage of Pyroptosis-Specific gasdermins in Cancer cells
by: William G. Herrick, et al.
Published: (2025-07-01) -
NCOA6 knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine
by: Jia Yuming, et al.
Published: (2025-03-01)